Short-term effect of intravitreal conbercept injection on major and macular branch retinal vein occlusion.

Abstract

ObjectiveTo evaluate the effectiveness of intravitreal conbercept injection on major and macular branch retinal vein occlusion (BRVO).MethodsThis retrospective analysis involved 43 patients with BRVO (major BRVO n = 24; macular BRVO, n = 19) who were diagnosed by fluorescein fundus angiography (FFA) and injected with intravitreal conbercept. The following outcomes were measured at baseline and follow-up (1-6 months): best-corrected visual acuity (BCVA), central foveal thickness (CFT), total retinal volume in a 6-mm diameter section of the macula, choroidal thickness under the central fovea of the macula, relative area of retinal hemorrhage, complications, and times when repeated injection was performed.ResultsThere were significant differences between the two groups in terms of BCVA, CFT, and total retinal volume in a 6-mm diameter section of the macula at 6 months after treatment. Choroidal thickness under the central fovea of the macula and relative area of retinal hemorrhage showed no significant differences between the two groups at 6 months after treatment; however, they significantly differed from baseline measurements.ConclusionIn general, intravitreal injection of conbercept may have a better short-term effect in patients with macular BRVO than in patients with major BRVO.